- Home
- CTMX
CTMX
CytomX Therapeutics Inc.
as 04-24-2025 4:00pm EST
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2015 |
| Target Price: | $5.52 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $5.85 | Next Earning Date: | 05-07-2025 |
| Revenue: | $138,103,000 | Revenue Growth: | 36.45% |
| Revenue Growth (this year): | -30.31% | Revenue Growth (next year): | -59.73% |
Stock Insider Trading Activity of CytomX Therapeutics Inc. (CTMX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CTMX | CEO | Mar 18 '25 | Sell | $0.60 | 37,656 | $22,555.94 | 995,195 | |
| ROWLAND LLOYD A | CTMX | General Counsel | Mar 18 '25 | Sell | $0.60 | 10,203 | $6,111.60 | 120,594 | |
| Ogden Christopher | CTMX | Chief Financial Officer | Mar 18 '25 | Sell | $0.60 | 8,551 | $5,122.05 | 201,026 | |
| BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Mar 18 '25 | Sell | $0.60 | 19,512 | $11,687.69 | 248,636 | |
| Chu Yu-Waye | CTMX | Chief Medical Officer | Mar 18 '25 | Sell | $0.60 | 4,025 | $2,410.98 | 135,725 |
Latest CytomX Therapeutics Inc. News
CTMX Breaking Stock News: Dive into CTMX Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
Zacks
20 days ago
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
Zacks
21 days ago
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
Zacks
a month ago
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
Zacks
a month ago
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
Zacks
a month ago
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Zacks
a month ago
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
Zacks
a month ago
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Compare CTMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTMX CytomX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.